Ruxolitinib — clinical trials using this drug

Public-registry trials using Ruxolitinib that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.

Ruxolitinib appears in 1 registered trial Eichor's radar has found, sponsored by Merck Sharp & Dohme LLC, the most recent registered as Phase 2 / Phase 3, with a planned enrollment of 380. Registered timeline: 2026–2032. The registry holds 365 registered studies for Polycythemia Vera.

Trial	Sponsor	Condition	Phase	Sites
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)	Merck Sharp & Dohme LLC	Polycythemia Vera	PHASE2 / PHASE3	0

About this study

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

Status	Not Yet Recruiting · planned start 2026-09
Primary completion	2032-06
Enrollment target	380 participants
Design	Randomized · Parallel · Phase 2 / Phase 3 · 2 arms
Who it enrolls	All sexes · 18 Years and older — full criteria are on the study record
Locations	not yet posted — the record updates as sites are announced

All fields verbatim from the ClinicalTrials.gov record for NCT07722611.

Origin & regulatory history

First FDA approval	JAKAFI — November 2011 (application NDA202192, currently held by INCYTE CORP)
Approval timeline	JAKAFI 2011 (INCYTE CORP) → OPZELURA 2021 (INCYTE CORP) → JAKAFI XR 2026 (INCYTE CORP)
Also known as	JAKAFI · OPZELURA · JAKAFI XR
Approved applications	3
Forms & routes	Cream, Tablet, Tablet, Extended Release · Oral, Topical
Registry-wide use	482 registered studies all-time · 113 currently recruiting

Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.

Polycythemia Vera drug landscape

The public registry holds 365 registered studies for Polycythemia Vera. Compounds appearing across the 200 most recently updated registry entries:

Placebo ×10 Laboratory Biomarker Analysis ×9 Momelotinib ×9 Best Available Therapy ×8 cyclophosphamide ×8 Pacritinib ×8 FEDRATINIB ×7 mycophenolate mofetil ×6 parsaclisib ×6 total-body irradiation ×6 busulfan ×5 Questionnaire Administration ×5 Ropeginterferon alfa-2b ×5 SAR302503 ×5 tacrolimus ×5 allogeneic hematopoietic stem cell transplantation ×4 Biospecimen Collection ×4 Bomedemstat ×4 fludarabine phosphate ×4 P1101 ×4 Carboplatin ×3 Flonoltinib ×3 Flonoltinib Maleate orally ×3 Fludarabine ×3 Hydroxyurea ×3 KRT-232 ×3 Low ×3 melphalan ×3 panobinostat ×3

Free site-risk snapshot for any of these trials

Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Related drugs & trials

Trialed alongside

← Eichor home · All tracked trials · Polycythemia Vera studies · Weekly briefs

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →